Micell Technologies has enrolled the first patient in the Dessolve II clinical trial (DES with Sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesions in the native coronary arteries). This trial is supporting CE Mark approval of the company's MiStent Drug-Eluting Coronary Stent System (MiStent DES).

The MiStent DES employs Micell's proprietary supercritical fluid technology, which applies a controlled absorbable polymer-active drug (sirolimus) matrix onto a cobalt-chromium stent.  The polymer dissolves and releases the drug into tissue in a controlled manner optimizing dosing throughout the affected artery. MiStent DES aims to minimize in-stent late lumen loss at nine months.